CY1117565T1 - Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak - Google Patents

Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak

Info

Publication number
CY1117565T1
CY1117565T1 CY20161100390T CY161100390T CY1117565T1 CY 1117565 T1 CY1117565 T1 CY 1117565T1 CY 20161100390 T CY20161100390 T CY 20161100390T CY 161100390 T CY161100390 T CY 161100390T CY 1117565 T1 CY1117565 T1 CY 1117565T1
Authority
CY
Cyprus
Prior art keywords
alk
fak
diaminopyridine
producer
double
Prior art date
Application number
CY20161100390T
Other languages
English (en)
Inventor
Martin J Jacobs
Gregory R Ott
Laurent Courvoisier
Shawn P Allwein
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117565(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of CY1117565T1 publication Critical patent/CY1117565T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση παρέχει μία ένωση τύπου (I) ή μία μορφή άλατος αυτής. Η ένωση τύπου (I) έχει δράση αναστολέα ALK και FAK και μπορεί να χρησιμοποιηθεί για αγωγή πολλαπλασιαστικών διαταραχών.
CY20161100390T 2012-03-06 2016-05-10 Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak CY1117565T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
EP13710258.8A EP2822939B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
CY1117565T1 true CY1117565T1 (el) 2017-04-26

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100390T CY1117565T1 (el) 2012-03-06 2016-05-10 Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak

Country Status (29)

Country Link
US (5) US9132128B2 (el)
EP (2) EP2822939B1 (el)
JP (2) JP6016953B2 (el)
KR (1) KR102068374B1 (el)
CN (2) CN106166155B (el)
AU (1) AU2013229995B2 (el)
CA (1) CA2865420C (el)
CL (1) CL2014002353A1 (el)
CY (1) CY1117565T1 (el)
DK (1) DK2822939T3 (el)
EA (2) EA025859B1 (el)
ES (2) ES2681487T3 (el)
HK (2) HK1205119A1 (el)
HR (1) HRP20160387T1 (el)
HU (1) HUE027976T2 (el)
IL (2) IL234239A (el)
ME (1) ME02460B (el)
MX (1) MX347772B (el)
MY (1) MY177290A (el)
NZ (1) NZ630251A (el)
PH (1) PH12014501979A1 (el)
PL (1) PL2822939T3 (el)
RS (1) RS54689B1 (el)
SG (2) SG10201507865QA (el)
SI (1) SI2822939T1 (el)
SM (1) SMT201600134B (el)
UA (1) UA115052C2 (el)
WO (1) WO2013134353A1 (el)
ZA (1) ZA201406147B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201507865QA (en) * 2012-03-06 2015-10-29 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
CN112996534A (zh) 2018-08-07 2021-06-18 因斯瑞拜奥有限公司 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
PL1660458T3 (pl) 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CA2642229C (en) * 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物
EP3012249A1 (en) * 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
MX2009011090A (es) * 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
CA2764653C (en) * 2009-06-10 2018-01-02 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
SG10201507865QA (en) * 2012-03-06 2015-10-29 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
UA115052C2 (uk) 2017-09-11
SI2822939T1 (sl) 2016-04-29
IL234239A (en) 2017-06-29
US20150374693A1 (en) 2015-12-31
RS54689B1 (en) 2016-08-31
IL252364B (en) 2018-03-29
PL2822939T3 (pl) 2016-08-31
SG10201507865QA (en) 2015-10-29
CN106166155B (zh) 2019-01-18
US9132128B2 (en) 2015-09-15
ME02460B (me) 2017-02-20
ES2681487T3 (es) 2018-09-13
EP2822939B1 (en) 2016-02-17
WO2013134353A8 (en) 2014-06-19
JP2015509540A (ja) 2015-03-30
US9623026B2 (en) 2017-04-18
JP2017039741A (ja) 2017-02-23
AU2013229995A1 (en) 2014-09-25
EP2822939A1 (en) 2015-01-14
IL252364A0 (en) 2017-07-31
AU2013229995B2 (en) 2017-04-13
EA025859B1 (ru) 2017-02-28
HUE027976T2 (en) 2016-11-28
US10111872B2 (en) 2018-10-30
PH12014501979B1 (en) 2014-11-24
EP3056494B1 (en) 2018-05-02
WO2013134353A1 (en) 2013-09-12
US20170173017A1 (en) 2017-06-22
SG11201405371PA (en) 2014-09-26
US9339502B2 (en) 2016-05-17
US10632119B2 (en) 2020-04-28
US20160243119A1 (en) 2016-08-25
CN104159894A (zh) 2014-11-19
MY177290A (en) 2020-09-10
EP3056494A1 (en) 2016-08-17
KR102068374B1 (ko) 2020-01-20
CN106166155A (zh) 2016-11-30
MX2014010613A (es) 2014-09-18
ZA201406147B (en) 2015-12-23
NZ630251A (en) 2016-02-26
DK2822939T3 (en) 2016-03-14
JP6016953B2 (ja) 2016-10-26
ES2570976T3 (es) 2016-05-23
SMT201600134B (it) 2016-07-01
HK1205119A1 (zh) 2015-12-11
US20150011561A1 (en) 2015-01-08
MX347772B (es) 2017-05-12
HK1226300A1 (zh) 2017-09-29
CA2865420A1 (en) 2013-09-12
EA201491641A1 (ru) 2015-04-30
CN104159894B (zh) 2016-09-07
KR20140138247A (ko) 2014-12-03
EA033124B1 (ru) 2019-08-30
US20190328735A1 (en) 2019-10-31
PH12014501979A1 (en) 2014-11-24
EA201691574A1 (ru) 2017-03-31
CA2865420C (en) 2020-06-02
CL2014002353A1 (es) 2015-01-09
HRP20160387T1 (hr) 2016-05-20

Similar Documents

Publication Publication Date Title
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
UA110338C2 (en) Chemical compounds
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
CR20130539A (es) Triazolopiridinas
MX2016002794A (es) Compuestos antiproliferativos.
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
BR112016024533A2 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase
EA201690844A1 (ru) Ингибиторы gsk-3
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201590250A1 (ru) Производные карбамат/мочевины
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
CY1117565T1 (el) Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201590656A1 (ru) Азаиндолины
EA201590729A1 (ru) Производные 3,4-дизамещенного оксазолидинона и их применение в качестве ингибиторов кальцийактивируемых калиевых каналов